FDA Approves Danaher Unit's Rapid Test for Hepatitis C
By Paul Ziobro
The Food and Drug Administration on Thursday granted marketing approval to Danaher's Cepheid unit for a rapid test for hepatitis C.
The approval is for Cepheid's Xpert HCV test and GeneXpert Xpress System, which the company said is the first test of the hepatitis C virus that can be used at certified point-of-care settings, such as certain use disorder treatment facilities, correctional facilities, syringe service programs, doctor's offices and urgent care clinics.
Instead of requiring a sample to be sent to a central lab, the test detects the virus's RNA and delivers results in less than about an hour using a blood sample from a fingertip.
Hepatitis C is a liver infection caused by a virus with the same name. It can either be a short-term illness or become a long-term chronic infection. According to estimates, more than 2.4 million people in the U.S. have hepatitis C, the company said.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
June 27, 2024 15:56 ET (19:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations